Zhengyu Zha

Optimizing clinical strategies for nutritional and immune indices prediction of chronic lung diseases: a cross-sectional study from NHANES 2007–2012

Song He, Cong Chen, Jianqi Hao, Yueli Shu et autres

BACKGROUND: Composite nutritional and immune indices (NIIs) have been associated with chronic lung diseases (CLDs). However, systematic research on their associations with different CLD subtypes and potential threshold patterns remains limited. OBJECTIVES: To examine cross-sectional associations between multiple NII and CLD subtypes, …

cn (code pays fourni par la source)

Author response for "Optimizing clinical strategies for nutritional and immune indices prediction of chronic lung diseases: A cross-sectional study from NHANES 2007-2012"

Song He, Cong Chen, Jianqi Hao, Yueli Shu et autres

Author response for "Optimizing clinical strategies for nutritional and immune indices prediction of chronic lung diseases: A cross-sectional study from NHANES 2007-2012"

Song He, Cong Chen, Jianqi Hao, Yueli Shu et autres

Author response for "Optimizing clinical strategies for nutritional and immune indices prediction of chronic lung diseases: A cross-sectional study from NHANES 2007-2012"

Song He, Cong Chen, Jianqi Hao, Yueli Shu et autres

Recent Advances in Nanomedicine: Cutting-Edge Research on Nano-PROTAC Delivery Systems for Cancer Therapy

Xiaoqing Wu, Yueli Shu, Peichuan Zhang, Yuxian Zou et autres

Proteolysis-targeting chimeras (PROTACs) selectively degrade target proteins by recruiting intracellular E3 ubiquitin ligases, overcoming the limitations of traditional small-molecule inhibitors that merely block protein function. This approach has garnered significant interest in precision cancer therapy. However, the clinical translation of PROTACs is …

cn (code pays fourni par la source)

RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer

Zhengyu Zha, Chunxiao Liu, Meisi Yan, Cong Chen et autres

Targeted therapy has achieved significant success in the treatment of non-small cell lung cancer (NSCLC), particularly in patients harboring common oncogenic driver mutations such as EGFR, KRAS, and ALK rearrangement. However, ~35-50% of NSCLC patients without tyrosine kinase mutation or rearrangement (non-mutated) …

cn, us, Éthiopie (code pays fourni par la source)

Multicellular ecotypes shape progression of lung adenocarcinoma from ground-glass opacity toward advanced stages

Yulan Deng, Liang Xia, Jian Zhang, Senyi Deng et autres

Lung adenocarcinoma is a type of cancer that exhibits a wide range of clinical radiological manifestations, from ground-glass opacity (GGO) to pure solid nodules, which vary greatly in terms of their biological characteristics. Our current understanding of this heterogeneity is limited. To …

cn, hk, us (code pays fourni par la source)

Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer

Jian Zhang, Kejia Zhao, Wenjing Zhou, Ran Kang et autres

Abstract Despite epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) have shown remarkable efficacy in patients with EGFR -mutant non-small cell lung cancer (NSCLC), acquired resistance inevitably develops, limiting clinical efficacy. We found that TET2 was poly-ubiquitinated by E3 ligase CUL7 …

cn (code pays fourni par la source)

Abstract 5286: RNase7-guided anti-ROS1 targeted therapy for hepatocellular carcinoma

Chunxiao Liu, Zhengyu Zha, Chenhao Zhou, Dihua Yu et autres

Abstract Oncogenic activation of c-ros oncogene 1 (ROS1) kinase due to gene fusion by chromosomal rearrangements was found in multiple cancers. The anti-ROS1 fusion gene is a successful therapeutic target with a 72% objective response rate in ROS1-rearranged NSCLC patients. However, it …

us, cn, tw (code pays fourni par la source)

Erratum to ‘Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma’ [J Hepatol 2021 (907-918)]

Chunxiao Liu, Zhengyu Zha, Chenhao Zhou, Yeh Chen et autres

us, cn, tw, Éthiopie (code pays fourni par la source)

612 Human ribonucleases act as potential plasma biomarkers for targeted therapy and immunotherapy in hepatocellular carcinoma

Chunxiao Liu, Zhengyu Zha, Chenhao Zhou, Dihua Yu et autres

Background Ribonucleases, known as RNases, are secreted in the circulatory system that are recognized as part of the host defense system against pathogens. Although RNases are involved in multiple physiologically and pathologically-relevant cell events, including cancer cell growth, stem cell self-renewal and …

us, tw, cn (code pays fourni par la source)

The N-terminal Phosphodegron Targets TAZ/WWTR1 Protein for SCF β-TrCP -dependent Degradation in Response to Phosphatidylinositol 3-Kinase Inhibition

Qun‐Ying Lei, Yue Xiong, Wei Huang, Ying Jiang et autres

The Hippo tumor suppressor pathway plays a major role in development and organ size control, and its dysregulation contributes to tumorigenesis. TAZ (transcriptional co-activator with PDZ-binding motif; also known as WWTR1) is a transcription co-activator acting downstream of the Hippo pathway, and …

us (code pays fourni par la source)